Featured
The Latest in Laser Treatment for Glaucoma
Promising new options could help patients get away from reliance on drops.
By Zarmeena Vendal, MD
Minimally Invasive Glaucoma Surgery in Uveitic Glaucoma
Is there hope or is it hype?
By Rebecca Chen, MD
Sustained-delivery Glaucoma Treatments
New innovations could bring more effective and safer options to patients.
By Galia Deitz, MD, Cara E. Capitena-Young, MD
News
Novel Retinal Tracer to Detect Amyloid Beta Enters Phase 2
A phase 2 study of Amydis Inc's novel retinal tracer AMDX-2011P for detecting amyloid beta in glaucoma patients has begun.
By Conni Koury, contributing writer
Survey Highlights Barriers Faced by Women in Ophthalmology
The Women in Ophthalmology survey was supported by Johnson & Johnson Vision.
By Conni Koury, contributing writer
Biodegradable Latanoprost Implant Promising in Phase 2a
Interim results were reported from an ongoing phase 2a clinical study of PolyActiva’s PA5108 biodegradable ocular implant.
By Conni Koury, contributing writer
7-year Data Show Trabecular Microbypass Benefits
Both standalone and combined use of trabecular microbypass resulted in significant IOP and medication reductions.
By Conni Koury, contributing writer
Black and Hispanic Glaucoma Patients 30% More Likely to Develop Poor Vision
Black, Hispanic, and Native American individuals have worse vision outcomes and less disease monitoring.
By Conni Koury, contributing writer
First Patient Treated in Phase 2 Study of Synthetic THC Prodrug for IOP Lowering
Skye Bioscience, Inc, initiated its phase 2 clinical trial evaluating SBI-100 for IOP.
By Conni Koury, contributing writer
SpyGlass Pharma's Long-term Bimatoprost Implant Studied in Phase 1/2 Trial
SpyGlass Pharma's intraocular drug delivery platform is designed to be implanted in glaucoma patients at the time of routine cataract surgery.
By Conni Koury, contributing writer
Pivotal Study Fully Enrolled for ViaLase Laser
The ViaLase laser combines a femtosecond laser and image guidance to create a conduit between Schlemm's canal and the anterior chamber.
By Conni Koury, contributing writer
Travoprost Implant Noninferior to Twice-daily Timolol 0.5% Drops
Data were presented at the 2023 annual meeting of the American Academy of Ophthalmology.
By Conni Koury, contributing writer
Travoprost Implant Lowered IOP Better Than Topical PGA Monotherapy
The mean IOP was 5.8 mmHg lower at screening.
By Conni Koury, contributing writer
No Significant ECD Loss Seen With Travoprost Implant
Data were presented at the 2023 American Academy of Ophthalmology meeting.
By Conni Koury, contributing writer
Surgical Exchange of Travoprost Implant Safe
Data could support readministration of the implant.
By Conni Koury, contributing writer
At 3 Years IOP Controlled in More Subjects With Travoprost Implant vs Topical Timolol
Data were presented at the 2023 meeting of the American Academy of Ophthalmology.
By Conni Koury, contributing writer
Combined Trabecular Microbypass and Goniotomy Effective
Data were presented at the 2023 annual meeting of the American Academy of Ophthalmology.
By Conni Koury, contributing writer
AI Can Predict Need for Glaucoma Surgery
Machine learning models based on electronic health record data can predict whether glaucoma patients will need surgery.
By Conni Koury, contributing writer
Metabolites May Hold Glaucoma Clues
Research was announced from the National Eye Institute.
By Conni Koury, contributing writer
6-year Data Demonstrate Effective, Sustained IOP Reduction With iTrack Canaloplasty
Results were reported in the Journal of Glaucoma.
By Conni Koury, contributing writer
Glaucoma Research Foundation Awards $2.5 Million in Grants
The foundation is granting the largest award budget in its history.
By Jennifer Ford, senior managing editor
Study Published of RadiusXR VR Perimetry Platform
Results show a 0.94 correlation in mean deviation and statistical noninferiority to traditional methods for staging glaucoma.
By Jennifer Ford, senior managing editor
Permanent J-code Assigned for iDose TR
The new level 2 J-code, J7355, will become effective July 1, 2024.
By Jim Gallagher, managing editor
Departments
From the Editor: Glaucoma’s Tipping Point
By Nathan M. Radcliffe, MD
Coding: Medicare Coverage of MIGS
A recent policy reversal for MIGS coverage by several Medicare Administrative Contractors raised questions about what’s next.
By Kevin J. Corcoran, COE, CPC, CPMA, FNAO
Product Spotlight: Canaloplasty Designed With Ergonomics in Mind
With iTrack Advance, only one hand is needed for procedures.
By Karen Appold, contributing writer
Web Exclusives
Cilioscleral Interposition Device for Intraocular Pressure Lowering
A new device grows the glaucoma arsenal while potentially preventing endothelial cell loss and inflammation.
By Philippe Sourdille, MD
iStent infinite Patient Selection
Cast a wider net when considering patients who might be a good fit for the iStent infinite.
By Inder Paul Singh, MD
The Evolving Standalone MIGS Landscape
The microinvasive glaucoma surgery landscape has evolved to the benefit of patients.
By Brent A. Kramer, MD
iStent infinite Surgical Technique: Tips, Tricks, and Pearls of Wisdom
A new design and surgical technique best practices for use as a standalone option or in conjunction with cataract surgery
By Benjamin L. Heller, DO